

Valeria Cento

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3962502/publications.pdf>

Version: 2024-02-01

71
papers

1,604
citations

331259

21
h-index

344852

36
g-index

74
all docs

74
docs citations

74
times ranked

3211
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. <i>Drug Resistance Updates</i> , 2018, 37, 17-39.	6.5	155
2	Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. <i>Nature Communications</i> , 2021, 12, 434.	5.8	102
3	Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0236311.	1.1	92
4	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
5	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652.	1.1	78
6	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. <i>Antiviral Research</i> , 2012, 93, 86-93.	1.9	71
7	Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. <i>Journal of Infection</i> , 2020, 81, e90-e92.	1.7	58
8	Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2781-2797.	1.4	55
9	Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. <i>Journal of Infectious Diseases</i> , 2012, 205, 557-567.	1.9	49
10	Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. <i>Archives of Virology</i> , 2011, 156, 1235-1243.	0.9	42
11	Drug Resistance Among Drug-naïve and First-line Antiretroviral Treatment-failing Children in Cameroon. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1062-1068.	1.1	41
12	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1a-4 in Italy. <i>Scientific Reports</i> , 2018, 8, 8988.	1.6	36
13	Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. <i>Journal of Medical Virology</i> , 2012, 84, 721-727.	2.5	31
14	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011, 43, 975-983.	0.4	28
15	Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. <i>Journal of General Virology</i> , 2013, 94, 143-149.	1.3	28
16	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28
17	HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. <i>Antiviral Research</i> , 2011, 90, 42-53.	1.9	27
18	SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. <i>BMC Infectious Diseases</i> , 2021, 21, 184.	1.3	25

#	ARTICLE	IF	CITATIONS
19	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. <i>Journal of Infection</i> , 2013, 67, 303-312.	1.7	23
20	Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. <i>Hepatology</i> , 2016, 63, 1058-1059.	3.6	23
21	Resistance to direct-acting antiviral agents. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 381-389.	1.5	22
22	Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 228-237.	0.9	22
23	Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions. <i>Journal of Medical Virology</i> , 2009, 81, 1627-1634.	2.5	21
24	Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. <i>BMC Evolutionary Biology</i> , 2017, 17, 70.	3.2	21
25	Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. <i>Journal of Medical Virology</i> , 2011, 83, 1565-1570.	2.5	20
26	Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. <i>Antiviral Research</i> , 2011, 92, 382-385.	1.9	19
27	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
28	Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology. <i>Journal of Medical Virology</i> , 2011, 83, 1752-1761.	2.5	18
29	A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy. <i>Antiviral Therapy</i> , 2013, 18, 1-5.	0.6	18
30	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vaccine – short- And long-term Immune reSponse evAluation in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	1.4	18
31	Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR?. <i>Viruses</i> , 2021, 13, 818.	1.5	15
32	Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine. <i>Hla</i> , 2022, 99, 183-191.	0.4	15
33	The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. <i>PLoS ONE</i> , 2013, 8, e53603.	1.1	14
34	Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 467-473.	0.7	14
35	Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. <i>Infection, Genetics and Evolution</i> , 2017, 53, 15-23.	1.0	14
36	The use of human immunodeficiency virus resistance tests in clinical practice. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1511-1517.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Nucleotide polymorphisms in the 5'UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. <i>Journal of Virological Methods</i> , 2013, 193, 205-208.	1.0	13
38	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	1.3	13
39	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. <i>Liver International</i> , 2017, 37, 653-661.	1.9	13
40	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017, 12, e0177352.	1.1	13
41	Viral resistance in HCV infection. <i>Current Opinion in Virology</i> , 2018, 32, 115-127.	2.6	13
42	Back to the future (of common respiratory viruses). <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 223-225.	0.9	13
43	Quantification of 1,3-β-D-glucan by Wako β-D-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. <i>Mycoses</i> , 2020, 63, 1299-1310.	1.8	12
44	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-3. <i>Liver International</i> , 2021, 41, 1802-1814.	1.9	12
45	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , 2015, 70, 288-298.	1.7	11
46	Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. <i>Clinical Infectious Diseases</i> , 2021, 72, 1868-1869.	2.9	11
47	Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3420-3424.	1.3	10
48	Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. <i>PLoS ONE</i> , 2020, 15, e0242765.	1.1	10
49	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
50	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. <i>Journal of Virus Eradication</i> , 2018, 4, 179-181.	0.3	9
51	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	2.0	8
52	Human papillomaviruses 53 and 66: Clinical aspects and genetic analysis. <i>Virus Research</i> , 2012, 163, 212-222.	1.1	7
53	Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. <i>Antiviral Research</i> , 2010, 88, 124-127.	1.9	6
54	HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1986-1998.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015, 47, 157-163.	0.4	5
56	In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from <i>Klebsiella pneumoniae</i> to <i>Serratia marcescens</i> in the lower respiratory tract. <i>Journal of Medical Microbiology</i> , 2020, 69, 82-86.	0.7	5
57	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. <i>Journal of Virus Eradication</i> , 2018, 4, 179-181.	0.3	5
58	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.	0.4	4
59	Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era. <i>Diagnostics</i> , 2021, 11, 809.	1.3	4
60	Rapid Detection and Quantification of <i>Mycobacterium tuberculosis</i> DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study. <i>Frontiers in Microbiology</i> , 2021, 12, 727774.	1.5	4
61	Sex differences in electrolyte imbalances caused by SARS-CoV-2: a cross-sectional study. <i>International Journal of Clinical Practice</i> , 2021, , e14882.	0.8	4
62	Viral Respiratory Infections: New Tools for a Rapid Diagnosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 747-758.	0.8	4
63	Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1231-1234.	0.8	3
64	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. <i>Viruses</i> , 2022, 14, 16.	1.5	3
65	HCV-RNA quantification in liver biopsic samples and extrahepatic compartments, using the abbott Real Time HCV assay. <i>Journal of Virological Methods</i> , 2017, 246, 1-7.	1.0	2
66	HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. <i>Infection</i> , 2018, 46, 717-720.	2.3	2
67	Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. <i>Viruses</i> , 2021, 13, 743.	1.5	2
68	1197 HCV GENOTYPES HAVE DIFFERENT GENETIC BARRIERS IN THE GENERATION OF RESISTANCE MUTATIONS TO PROTEASE INHIBITORS IN ADVANCED CLINICAL DEVELOPMENT. <i>Journal of Hepatology</i> , 2011, 54, S473.	1.8	1
69	Prolongation of incubation time improves clinical diagnosis of <i>Mycobacterium xenopi</i> infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 533-537.	0.9	1
70	May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics. <i>New Microbiologica</i> , 2015, 38, 491-7.	0.1	1
71	Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. <i>New Microbiologica</i> , 2019, 42, 69-80.	0.1	0